OmniAb, Inc. (NASDAQ:OABI) CEO Sells $135,467.64 in Stock

OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr sold 41,811 shares of OmniAb stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $135,467.64. Following the sale, the chief executive officer now owns 3,749,639 shares in the company, valued at $12,148,830.36. The trade was a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

OmniAb Price Performance

Shares of OABI opened at $3.20 on Friday. OmniAb, Inc. has a 1 year low of $3.11 and a 1 year high of $6.55. The stock has a 50 day simple moving average of $3.66 and a two-hundred day simple moving average of $4.06. The firm has a market cap of $451.89 million, a P/E ratio of -5.16 and a beta of -0.10.

Analysts Set New Price Targets

A number of research firms have recently commented on OABI. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of OmniAb in a research note on Thursday, November 14th. Benchmark restated a “buy” rating and issued a $8.00 price objective on shares of OmniAb in a research note on Thursday, November 14th.

Hedge Funds Weigh In On OmniAb

A number of hedge funds and other institutional investors have recently made changes to their positions in OABI. CWC Advisors LLC. bought a new position in shares of OmniAb during the third quarter valued at approximately $54,000. Walleye Capital LLC bought a new position in shares of OmniAb during the third quarter valued at approximately $61,000. Intech Investment Management LLC bought a new position in shares of OmniAb during the third quarter valued at approximately $70,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of OmniAb by 64.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock valued at $96,000 after acquiring an additional 8,909 shares in the last quarter. Finally, Palumbo Wealth Management LLC raised its holdings in shares of OmniAb by 12.5% during the third quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock valued at $104,000 after acquiring an additional 2,744 shares in the last quarter. Institutional investors own 72.08% of the company’s stock.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.